secwatch.observer — SEC 8-K summary
======================================

Issuer:     Envoy Medical, Inc. (COCH)
CIK:        0001840877
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001213900-25-096845
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Envoy Medical gets FDA nod to expand pivotal Acclaim cochlear implant trial to final stage
--------------------------------------------------------------------------------

- FDA approved expansion based on 3-month data from first 10 patients; no SAEs or UADEs reported.
- Final stage will add 46 participants across 7 U.S. sites; full enrollment expected by early 2026.
- Timeline shortened by 3–6 months, reducing anticipated capital need by $10–$15 million.
- Preliminary data showed Acclaim can achieve effectiveness for proposed intended use in cochlear-implant-only condition.
- Company believes fully implanted design addresses 95% of eligible adults who have not received a cochlear implant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840877/000121390025096845/0001213900-25-096845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840877/000121390025096845/ea0260494-8k_envoy.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-096845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer